Imaging Biometrics seeks FDA clearance for IB Zero G

By staff writers

May 31, 2022 -- Advanced visualization software developer Imaging Biometrics has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its IB Zero G artificial intelligence-based software application.

IB Zero G is designed to eliminate the need for gadolinium-based contrast agents (GBCAs) in routine MRI exams, according to the vendor. The company received a patent in 2021 for the software.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking